X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1416) 1416
Publication (107) 107
Newsletter (38) 38
Book Review (15) 15
Magazine Article (5) 5
Book Chapter (4) 4
Newspaper Article (2) 2
Paper (2) 2
Data Set (1) 1
Dissertation (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fenofibrate (905) 905
male (719) 719
humans (688) 688
index medicus (652) 652
animals (471) 471
fenofibrate - administration & dosage (439) 439
female (419) 419
pharmacology & pharmacy (415) 415
middle aged (352) 352
fenofibrate - therapeutic use (335) 335
fenofibrate - pharmacology (307) 307
hypolipidemic agents - administration & dosage (294) 294
hypolipidemic agents - therapeutic use (259) 259
adult (256) 256
rats (251) 251
mice (207) 207
aged (197) 197
cholesterol (195) 195
drug therapy, combination (190) 190
hypolipidemic agents - pharmacology (183) 183
triglycerides - blood (166) 166
lipids (161) 161
research (140) 140
dosage and administration (135) 135
risk factors (131) 131
fenofibrate - adverse effects (130) 130
hyperlipidemias - drug therapy (125) 125
diabetes (124) 124
treatment outcome (123) 123
hypolipidemic agents - adverse effects (119) 119
dyslipidemia (117) 117
lipids - blood (117) 117
fenofibrate - pharmacokinetics (116) 116
drug therapy (115) 115
endocrinology & metabolism (115) 115
solubility (115) 115
metabolism (114) 114
triglycerides (114) 114
dyslipidemias - drug therapy (112) 112
statins (109) 109
cardiac & cardiovascular systems (104) 104
ppar-alpha (101) 101
fibric acids (100) 100
atherosclerosis (98) 98
ppar alpha - agonists (98) 98
cholesterol - blood (97) 97
health aspects (97) 97
biochemistry & molecular biology (95) 95
fenofibrate - chemistry (95) 95
hyperlipidemia (95) 95
coronary-heart-disease (92) 92
dose-response relationship, drug (90) 90
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (90) 90
liver - drug effects (90) 90
rats, sprague-dawley (90) 90
rats, wistar (90) 90
atorvastatin (87) 87
cholesterol, ldl - blood (87) 87
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (87) 87
liver - metabolism (86) 86
metabolic syndrome (85) 85
administration, oral (84) 84
analysis (84) 84
cholesterol, hdl - blood (84) 84
expression (84) 84
liver (84) 84
therapy (84) 84
drugs (83) 83
fenofibrate - analogs & derivatives (83) 83
simvastatin (83) 83
oxidative stress (82) 82
bioavailability (80) 80
cardiovascular-disease (80) 80
inflammation (80) 80
rodents (80) 80
care and treatment (79) 79
double-blind method (79) 79
risk (79) 79
hypolipidemic agents - pharmacokinetics (75) 75
ppar alpha - metabolism (75) 75
biological availability (73) 73
insulin resistance (73) 73
type 2 diabetes (71) 71
dissolution (70) 70
drug delivery systems (69) 69
medicine, general & internal (69) 69
diet (68) 68
disease models, animal (67) 67
gemfibrozil (67) 67
article (66) 66
medicine (66) 66
particle size (65) 65
cardiovascular disease (63) 63
pharmacokinetics (63) 63
diabetes mellitus, type 2 - drug therapy (62) 62
disease (62) 62
medicine, research & experimental (62) 62
physiological aspects (61) 61
chemistry, medicinal (60) 60
mice, inbred c57bl (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1379) 1379
Spanish (14) 14
Russian (13) 13
French (11) 11
Japanese (11) 11
Korean (7) 7
Czech (6) 6
Polish (6) 6
German (5) 5
Chinese (4) 4
Hungarian (4) 4
Croatian (1) 1
Portuguese (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 11/2015, Volume 495, Issue 1, pp. 9 - 18
Oral drug delivery is the most preferred route for patients; however, the low solubility of drugs and the resultant poor absorption compromise the benefits of... 
Absorption mechanism | Nanoemulsions | Insoluble drug | Pharmacokinetics | Globular protein | Solidification | MECHANISM | VIVO | NANOCARRIERS | MICELLES | FORMULATION | DIRECT CYTOSOLIC DELIVERY | TRANSPORT | NANOSUSPENSIONS | PHARMACOLOGY & PHARMACY | ABSORPTION | Nanoparticles - chemistry | Soybean Proteins - pharmacokinetics | Emulsions - adverse effects | Humans | Bile Acids and Salts - chemistry | Drug Carriers - administration & dosage | Biological Availability | Fenofibrate - chemistry | Soybean Proteins - chemistry | Drug Carriers - chemistry | Intestinal Absorption | Tissue Distribution | Emulsions - administration & dosage | Bile Acids and Salts - administration & dosage | Protein Denaturation | Water - chemistry | Bile Acids and Salts - pharmacokinetics | Caco-2 Cells | Cell Survival - drug effects | Soybean Proteins - administration & dosage | Administration, Oral | Emulsions - chemistry | Nanoparticles - ultrastructure | Solubility | Fenofibrate - administration & dosage | Rats | Chemistry, Pharmaceutical | Fenofibrate - blood | Particle Size | Fenofibrate - pharmacokinetics | Animals | Suspensions - pharmacokinetics | Drug Carriers - pharmacokinetics | Nanoparticles - administration & dosage | Emulsions - pharmacokinetics | Drugs | Drug delivery systems | Analysis | Gastrointestinal system | Vehicles
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 05/2016, Volume 99, Issue 5, pp. 538 - 547
Drug–drug interactions causing severe hypoglycemia due to antidiabetic drugs is a major clinical and public health problem. We assessed whether sulfonylurea... 
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypoglycemia - epidemiology | Glipizide - administration & dosage | Humans | Middle Aged | Glipizide - adverse effects | Male | Fenofibrate - adverse effects | Incidence | Drug Interactions | Hypoglycemic Agents - administration & dosage | Female | Retrospective Studies | Sulfonylurea Compounds - administration & dosage | Glyburide - administration & dosage | Hypoglycemia - chemically induced | Glyburide - adverse effects | Severity of Illness Index | Hypolipidemic Agents - adverse effects | Fenofibrate - administration & dosage | Sulfonylurea Compounds - adverse effects | Algorithms | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hypolipidemic Agents - administration & dosage | Aged | Hypoglycemic Agents - adverse effects | Cohort Studies | GEMFIBROZIL | GLYCEMIC CONTROL | CHEMISTRY, MEDICINAL | PROPENSITY SCORE | GLUCOSE-METABOLISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | PRAVASTATIN | TYPE-2 DIABETES-MELLITUS | INSULIN SENSITIVITY | GLYBURIDE | CORONARY-ARTERY-DISEASE | DRUG-INDUCED HYPOGLYCEMIA | Care and treatment | Dosage and administration | Management | Hypoglycemia | Hypoglycemic sulfonylureas | Sulfonylurea compounds | Risk factors | Public health | drug interactions | fibric acids | sulfonylurea compounds | hypoglycemia | cohort studies | hydroxymethylglutaryl-CoA reductase inhibitors | Medicaid | pharmacoepidemiology | propensity score
Journal Article
NEFROLOGIA, ISSN 0211-6995, 03/2017, Volume 37, Issue 2, pp. 216 - 217
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 12/2010, Volume 30, Issue 12, pp. 2666 - 2672
Journal Article
Cardiovascular Therapeutics, ISSN 1755-5914, 08/2014, Volume 32, Issue 4, pp. 139 - 146
Summary Introduction Oxidative stress plays an important role in atherosclerosis. Both F2‐isoprostane (8‐iso‐PGF2a) and oxidized low‐density lipoprotein... 
nicotinic acid/laropiprant | fenofibrate | oxidized LDL | F2‐Isoprostanes | rosuvastatin | oxidative stress | mixed dyslipidemia | Fenofibrate | Oxidative stress | Nicotinic acid/laropiprant | Oxidized LDL | F2-Isoprostanes | Rosuvastatin | Mixed dyslipidemia | CARDIAC & CARDIOVASCULAR SYSTEMS | ACID | ATHEROSCLEROSIS | RISK | APOLIPOPROTEINS | COMBINATION | HIGH-DENSITY-LIPOPROTEIN | THERAPY | PHARMACOLOGY & PHARMACY | CIRCULATING OXIDIZED LDL | AUTOANTIBODY | HYPOLIPIDEMIC TREATMENT | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Dinoprost - blood | Prospective Studies | Humans | Middle Aged | Apolipoprotein B-100 - blood | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Fenofibrate - adverse effects | Greece | Niacin - administration & dosage | Dyslipidemias - blood | Time Factors | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Niacin - adverse effects | Female | Dinoprost - analogs & derivatives | Uric Acid - blood | Drug Therapy, Combination | Dyslipidemias - diagnosis | Hypolipidemic Agents - adverse effects | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Fenofibrate - administration & dosage | Rosuvastatin Calcium | Treatment Outcome | Biomarkers - blood | Atorvastatin Calcium | Bilirubin - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Indoles - adverse effects | Hypolipidemic Agents - administration & dosage | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Oxidative Stress - drug effects | Lipoproteins, LDL - blood | Sulfonamides - administration & dosage | Care and treatment | Low density lipoproteins | Analysis | Simvastatin | Atherosclerosis | Fibric acids | Cardiovascular agents | Index Medicus
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 01/2018, Volume 27, Issue 1, pp. 30 - 37
Purpose The Heart Protection Study 2—Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2‐THRIVE) trial found higher incidence rates of adverse... 
niacin | sentinel | bleeding | safety | pharmacoepidemiology | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | THERAPY | EXTENDED-RELEASE NIACIN/LAROPIPRANT | MODELS | PHARMACOLOGY & PHARMACY | LAROPIPRANT | United States - epidemiology | Hyperlipidemias - blood | United States Food and Drug Administration - statistics & numerical data | Follow-Up Studies | Humans | Middle Aged | Male | Gastrointestinal Hemorrhage - epidemiology | Delayed-Action Preparations - administration & dosage | Fenofibrate - adverse effects | Incidence | Niacin - administration & dosage | Young Adult | Aged, 80 and over | Niacin - adverse effects | Adult | Female | Adverse Drug Reaction Reporting Systems - statistics & numerical data | Hypolipidemic Agents - adverse effects | Hyperlipidemias - drug therapy | Fenofibrate - administration & dosage | Gastrointestinal Hemorrhage - chemically induced | Delayed-Action Preparations - adverse effects | Intracranial Hemorrhages - chemically induced | Hypolipidemic Agents - administration & dosage | Cholesterol, HDL - blood | Intracranial Hemorrhages - epidemiology | Aged | Niacin | Analysis | Safety and security measures | Sensitivity analysis | Initiators | Sentinel system | Data processing | Hazards | Hemorrhage | Bleeding | Confidence intervals | Fenofibrate | Statistical models | Vitamin B | Lipoproteins (high density)
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 04/2014, Volume 61, Issue 4, pp. 636 - 642
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2006, Volume 47, Issue 8, pp. 1584 - 1587
Journal Article